Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Design and Evaluation of Therapeutic Oligonucleotides for Acute Myeloid Leukemia

FY 2020-21

Summary
11 000 individuals this year alone will die from Acute Myeloid Leukemia (AML). AML is a rapidly progressing and ruthless blood cancer. In AML, the bone marrow produces immature blood cells that cannot carry out the function of healthy cells, leading to symptoms such as anemia, infection, and bleeding. Even with contemporary therapies, only ~ 30% of cases are cured. The goal of this project is to develop and validate a novel strategy for the treatment of AML using a new class of drugs: therapeutic oligonucleotides (TOs). TOs work by directly altering the expression of currently ""undruggable"" genes. Two different TO strategies will be tested: 1) decreasing gene expression using duplex small-interfering RNA (siRNA); 2) increasing gene expression using small-activating RNA (saRNA). A prime target of TOs in AML is PU.1, an essential factor in the production of specific blood cell types. Over half of AML patients have low PU.1 levels. It would be advantageous to increase the expression of PU.1 in such AML patients. Therefore, PU.1-targeted TOs will be designed, optimized, and tested in such cases. Developing saRNA and siRNA therapies can allow for the improved treatment of currently extremely difficult to cure AMLs, moving towards a future with more survivors.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449713
Name
Kovecses Olivia
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Design and Evaluation of Therapeutic Oligonucleotides for Acute Myeloid Leukemia
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Hematopoiesis; Rna Therapy; Small Activating Rna; Small Interfering Rna; Transcription Factor
Abstract
11 000 individuals this year alone will die from Acute Myeloid Leukemia (AML). AML is a rapidly progressing and ruthless blood cancer. In AML, the bone marrow produces immature blood cells that cannot carry out the function of healthy cells, leading to symptoms such as anemia, infection, and bleeding. Even with contemporary therapies, only ~ 30% of cases are cured. The goal of this project is to develop and validate a novel strategy for the treatment of AML using a new class of drugs: therapeutic oligonucleotides (TOs). TOs work by directly altering the expression of currently ""undruggable"" genes. Two different TO strategies will be tested: 1) decreasing gene expression using duplex small-interfering RNA (siRNA); 2) increasing gene expression using small-activating RNA (saRNA). A prime target of TOs in AML is PU.1, an essential factor in the production of specific blood cell types. Over half of AML patients have low PU.1 levels. It would be advantageous to increase the expression of PU.1 in such AML patients. Therefore, PU.1-targeted TOs will be designed, optimized, and tested in such cases. Developing saRNA and siRNA therapies can allow for the improved treatment of currently extremely difficult to cure AMLs, moving towards a future with more survivors.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kovecses, Olivia
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~